Medtronic Concerto™/Virtuoso™ Debut

The FDA has approved two new products by Medtronic, Inc., the company is reporting today. Both products have capabilities to deliver remote wireless telemetry. The press release explains:

The Concerto cardiac resynchronization therapy-defibrillator (CRT-D) and Virtuoso implantable cardioverter defibrillator (ICD) are the first implantable cardiac devices available with Medtronic’s proprietary Conexus™ Wireless Telemetry, developed using the Medical Implant Communications Service (MICS, 402-405 MHz). Using the MICS band enables reliable communication between the implanted device and clinician programmers and patient home monitoring units.
Conexus Telemetry will enhance efficiencies at device implant and during in-office follow-up visits. At implant, there is no need for the programmer head to enter the sterile implant field, and in-office visits may be simplified when they’re needed, as the physician can interrogate patients’ devices via wireless telemetry without the need for surface electrodes. As well, Conexus Telemetry will enable automatic, wireless data transmission from the patient’s device to a home monitor. Device data then will be transmitted to the clinician using the Medtronic CareLink® Network, the first Internet-based system to help physicians and patients better manage chronic cardiovascular disease treated by implantable device therapy. Communication between device and monitor will be initiated by physician-programmed device parameters or it can occur on pre-scheduled dates that are pre-programmed via the Medtronic CareLink Network. If the system detects notable changes in the patient’s condition or device status, a Medtronic CareAlert™ will be sent to the physician, providing the potential for treatment decisions before the condition worsens.

More details in the press release…
The video press release…
Company’s inaugural site for its Conexus™ Wireless Telemetry line is not operational yet, as it gives an error… (link)UPDATE (5/17/06): Conexus™ Wireless Telemetry site is now operational.

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around

more

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around the world to participate in the upcoming “2nd World Congress on Advanced Cancer Science & Therapy” to be held at Dubai, UAE during January 28-29, 2019. The meeting for this year will revolve around the theme “An Assembly of Curious Facts and Cure for Cancer” thus relaying the most cutting-edge findings in this field.

The two-day meeting is going to be an event to look forward for its enlightening symposiums & workshops from established experts in cancer therapy, potential keynote talks from eminent speakers, informative oral sessions and innovative poster presentations.

Cancer Therapy 2019 is an extraordinary event that invites participants from different leading universities, clinical research institutions and various diagnostic companies to share their research experiences in all aspects of this rapidly expanding field and provides an opportunity to meet and communicate with leading doctors, surgeons, scientists, academic professionals from around the world and listen to top speakers on new developments that impact and advance future of cancer science. It serves as a global platform to know about the current developments and new approaches in the field of cancer science and therapy. It will also prove to be a brilliant open door for businesses keen on expanding their global market reach. This event is an effort to understand the underlying new techniques which are amended to increase effectiveness, accuracy, sustainability, and quality of life.